Paris, January 2026 — Meta Cell Technology (MCT) concludes a high-engagement scientific presence at IMCAS World Congress 2026 (Palais des Congrès, Paris, January 29–31), contributing to clinical dialogue in regenerative medicine through evidence-led exchange and critical discussion.
IMCAS World Congress is widely recognized as a leading international meeting in aesthetic, plastic, and regenerative medicine, convening physicians, researchers, and industry stakeholders from across the globe. In 2026, scientific debate around regenerative biology, clinical translation, and responsible communication remained central themes.
At Booth D130, MCT hosted the MCT Booth Talks under the concept “Faces & Voices of Regenerative Aesthetics”—a structured format designed to prioritize peer-to-peer scientific discussion over promotional messaging. Across 13 Booth Talks, international physicians from six countries—Spain, Italy, Brazil, Qatar, Argentina, and Colombia—shared clinical perspectives and engaged in scientific discussion around regenerative approaches, with an emphasis on biological mechanisms, evidence quality, and practical considerations in medical practice.
Attendance across the sessions was consistently at full booth capacity, reflecting strong interest from the international medical community in rigorous, clinically grounded dialogue.
Dr. Hernán Pinto (Argentina) contributed to the scientific conversation both at the MCT Booth Talks—addressing autologous exosomes and photothermal biomodulation—and as an invited speaker in the Grand Amphitheatre, where his lecture highlighted the importance of scientific rigor, clear terminology, and responsible communication in a field often affected by overstated claims. His participation reflected MCT’s commitment to supporting critical thinking and evidence-based standards in regenerative medicine.
In the days leading up to IMCAS World Congress 2026, Meta Cell Technology was also referenced in editorial coverage by The Times, reflecting growing international attention on regenerative medicine and the importance of evidence-based approaches within the field.
MCT thanks the physicians, speakers, partners, and attendees who joined these discussions at IMCAS 2026. The company will continue to expand its scientific and educational initiatives throughout the year, focused on clinically relevant dialogue and responsible innovation in regenerative medicine.
About Meta Cell Technology (MCT)
Meta Cell Technology develops medical devices and clinical protocols for evidence-led regenerative practice, supporting structured scientific exchange and responsible clinical translation.
